Yungjin Pharm영진약품
003520 · KOSPI · ₩003520 · 영진약품
- Market cap
- ₩175B
- Enterprise value
- ₩225B
- P/E
- —
- P/B
- 2.0×
- Dividend yield
- 0.0%
- ROE
- −7.3%
- Net margin
- −2.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−58.8% from the high
₩944Today: ₩944 – ₩969₩2,320
Returns
- 1W−5.7%
- 1M−6.6%
- 3M−19.0%
- 6M−46.4%
- YTD−52.3%
- 1Y−53.1%
- Volume today
- 285,784
- 1.1× the 20-day average
- Traded today
- ₩273M
- Listed shares
- 182,892,731
- EPS (12 months)
- −₩34
- Earnings yield −3.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- MomentumWeak-6.3% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Yungjin Pharm stock overview
Yungjin Pharm (영진약품, KRX: 003520) is listed on KOSPI, in the Biotech & Pharma sector. Youngjin Pharmaceutical is a Korean pharmaceutical company that is a core affiliate of the KT&G group, focusing on prescription medicines and its biopharma business. Its shares closed at ₩955 on Oct 27, 2026, up 1.06% on the day, giving it a market value of ₩175B.
Key facts
- Market cap
- ₩175B
- Sector
- Biotech & Pharma
- Latest price change
- +1.06%
- As of
- Oct 27, 2026
- Main business
- Youngjin Pharmaceutical is a Korean pharmaceutical company that is a core affiliate of the KT&G group, focusing on prescription medicines and its biopharma business.
Quick answers about Yungjin Pharm
- What does Yungjin Pharm do?
- Youngjin Pharmaceutical is a Korean pharmaceutical company that is a core affiliate of the KT&G group, focusing on prescription medicines and its biopharma business. Its main products span antibiotics, parenteral and enteral nutrition products, cardiovascular, neuropsychiatric, antipyretic and analgesic, digestive, and respiratory drugs, and it also supplies active pharmaceutical ingredients and contract manufacturing (CMO) services. It sells mainly in South Korea and also exports, with Japan being its largest overseas market.
- What is the market cap of Yungjin Pharm?
- The market capitalisation of Yungjin Pharm was ₩175B at the close on Oct 27, 2026.
- Who are the largest shareholders of Yungjin Pharm?
- According to the latest official filings, the largest reported holders are VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.59%, as of Jul 31, 2026); National Pension Service (0.49%, as of Dec 31, 2025); VANGUARD DEVELOPED MARKETS INDEX FUND (0.46%, as of Jun 30, 2026).
- When is the next earnings report from Yungjin Pharm?
- Korean companies rarely announce results dates in advance. Based on when Yungjin Pharm filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Yungjin Pharm?
- Yes. The National Pension Service held 0.49% of Yungjin Pharm shares as of Dec 31, 2025.
Company profile
Youngjin Pharmaceutical is a Korean pharmaceutical company that is a core affiliate of the KT&G group, focusing on prescription medicines and its biopharma business. Its main products span antibiotics, parenteral and enteral nutrition products, cardiovascular, neuropsychiatric, antipyretic and analgesic, digestive, and respiratory drugs, and it also supplies active pharmaceutical ingredients and contract manufacturing (CMO) services. It sells mainly in South Korea and also exports, with Japan being its largest overseas market.
Written by AI from the company's latest annual report.
- Korean name
- 영진약품
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- Business group
- KT&G
- CEO
- 이기수
- Founded
- Jul 1962
- Listed
- Jun 1973
- Listed shares
- 182,892,731
- Fiscal year ends
- Month 12
- Website
- www.yungjin.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Amended: Major sales or supply contractOct 8, 2026
- Lawsuit filed or ruledSep 1, 2026
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]Aug 28, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation BodiesAug 13, 2026
Titles in Korean until English translations are added.
Also known as: Yungjin Pharm / 영진약품 / 003520 / KRX:003520
Source: KRX statistical information